Cellectis’ Post

🚨 NEWS 🚨 The @US_FDA grants rare disease designation to SLS009, an investigational highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia. The decision is based on the favorable safety profile of SLS009 in clinical trials. Read more here 👉 https://loom.ly/8UVxgeY #ALLsm #leusm #MedNews

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

Exploring Therapy-Related Myeloid Neoplasms in Acute Promyelocytic Leukemia Survivors 🔬 New Insights in Hematopathology 🔬 A recent study published in the Journal of Hematopathology sheds light on the incidence of therapy-related myeloid neoplasms (t-MNs) in patients treated for acute promyelocytic leukemia (APL). The research highlights: Incidence Rates: The occurrence of t-MNs post-APL treatment. Therapeutic Correlation: How different treatment regimens impact the development of t-MNs. Future Directions: Potential improvements in treatment protocols to mitigate risks. This study is crucial for advancing our understanding and improving patient outcomes in hematopathology. 📈 #Hematopathology #Leukemia #MedicalResearch #HealthcareInnovation

T-cell acute lymphoblastic leukemia (T-ALL) It is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the bone marrow. T-ALL accounts for about 15% of pediatric cases and 20% of adults cases. The incidence increases with age. Tetraploidy is observed in about 3% of patients. Frequency: t(7;14)5%, t(8;14)2%, t(10;14)5%, t(11;14)1%.

🌟 Exploring hope on the horizon: Zanubrutinib and #ChronicLymphoidLeukemia 🌟 Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disease that is characterized by the proliferation of monoclonal B-cells. It accounts for 25 to 30% of leukemia cases in the United States. In the past, patients were given chemo-immunotherapy regimens based on FCR, BR, or chlorambucil. However, these regimens may cause relapse or recurrence in CLL patients. To overcome this limitation, there is continuous research for the development of newer drugs. 💪 The Food and Drug Administration (FDA) approved zanubrutinib available under the trade name Brukinsa® for the treatment of chronic lymphoid leukemia and small cell lymphomas. Recent studies have shown promising results, highlighting zanubrutinib's efficacy in targeting CLL cells while potentially minimizing side effects. 📈 Dive into our blog @ https://lnkd.in/drdfPESw to delve deeper into zanubrutinib and its potential as a CLL treatment, offering promising effects with manageable side effects. #CLLAwareness #Zanubrutinib #NewHope #FightAgainstCancer #Fludarabine #Cyclophosphamide #Rituximab #Bendamustine #Rituximab #Chlorambucil #BCellReceptor #TargetTherapy #RefractoryCases #ImmuneCells #LymphoidLeukemiaTreatment #BTKInhibitor #LymphoidLeukemiaSymptoms #LymphoidLeukemia #ClinicalTrails #Bhimar #LifeSciences #Healthcare #Informations #Omics #Oncology #Neurology

#News for #Investors and #Media: our BTK inhibitor is now reimbursed for eligible patients with chronic lymphocytic leukemia in Lithuania, where reimbursement timelines are markedly longer compared to other European countries according to the W.A.I.T Indicator report published by IQVIA. This milestone is a testament to our commitment to expanding access to innovative medicines for patients around the world. #CLL #PatientsFirst  

Venetoclax (a BCL2 inhibitor) is a very effective treatment for chronic lymphocytic leukemia (CLL) in individuals with no prior exposure to BTK inhibitors (BTKi). However, it is less effective for those whose disease has progressed on prior BTKi therapy. https://bit.ly/3uDZYGo

In the field of hematology, few are as dedicated as #StanDOM's Peter Greenberg and Gabriel Mannis. Greenberg's extensive work on myelodysplastic syndromes (MDS) has transformed our understanding of this complex disease. Meanwhile, Mannis is making strides in acute myeloid leukemia (AML) research, with nearly a dozen clinical trials underway. Together, they exemplify the pursuit of knowledge in hematologic diseases! Learn more about their impactful work and the advancements in hematology! 👇 https://lnkd.in/ek_hQH9i

On World Sickle Cell Day, let's raise awareness about sickle cell disease. Dr. Stalin Ramprakash, Consultant in Paediatric Haematology, Oncology, and BMT, discusses this inherited disease in his video. Sickle cell disease affects millions globally and has severe impacts on health and lifespan. Screening, early intervention, and treatments like hydroxyurea can help manage symptoms. The only current cure is a bone marrow transplant, offering hope for a normal life. Let's support ongoing care and research for better outcomes. #SickleCellAwareness #WorldSickleCellDay #SickleCellResearch #HealthAwareness #SickleCellSupport #BoneMarrowTransplant #AsterCMI #AsterBangalore #AsterHospitals

Medicare Part D Smoothing Program: Impact on Access and Adherence: The discussion explores how Medicare's Part D smoothing program in 2025 might impact chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies and how pharmacists can help navigate this new program. The session concludes with closing remarks. #finance #pharmacy #lifesciences